ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Kirin leans into health products and drugs, pouring in $900m

Majority of growth investment set aside for these segments for 1st time

Kirin's iMUSE series of health drinks contain lactic acid bacteria said to have immunity benefits.

TOKYO -- Beverage group Kirin Holdings is shifting focus to health and pharmaceuticals, allocating more of its medium-term growth investment for these segments than for beer and soft drinks for the first time.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more